Article

Relationship between Prognostic Stage in Breast Cancer and Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography

Mio Mori 1, Tomoyuki Fujioka 1, Kazunori Kubota 2, Leona Katsuta 1, Yuka Yamaga 1, Kyoko Nomura 1, Emi Yamaga 1, Junichi Tsuchiya 1, Tokuko Hosoya 3, Goshi Oda 3, Tsuyoshi Nakagawa 3, Ichiro Onishi 4 and Ukihide Tateishi 1

1 Department of Diagnostic Radiology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan; m_mori_116@yahoo.co.jp (M.M.); fjokmrad@tmd.ac.jp (T.F.); leonah@com.home.ne.jp (L.K.); 11.ruby.89@gmail.com (Y.Y.); nomura.kyoko@kameda.jp (K.N.); ymgdmm@tmd.ac.jp (E.Y.); tuwu11@gmail.com (J.T.); ttsidrnm@tmd.ac.jp (U.T.)
2 Department of Radiology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama 343-8555, Japan
3 Department of Surgery, Breast Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan; tocco_nkgw@yahoo.co.jp (T.H.); oda.srg2@tmd.ac.jp (G.O.); nakagawa.srg2@tmd.ac.jp (T.N.)
4 Department of Comprehensive Pathology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan; ichipth2@tmd.ac.jp
* Correspondence: kubotard@dokkyomed.ac.jp; Tel.: +81-48-965-1111

Abstract: This retrospective study examined the relationship between the standardized uptake value max (SUVmax) of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and the prognostic stage of breast cancer. We examined 358 breast cancers in 334 patients who underwent 18F-FDG PET/CT for initial staging between January 2016 and December 2019. We extracted data including SUVmax of 18F-FDG PET and pathological biomarkers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and nuclear grade. Anatomical and prognostic stages were determined per the American Joint Committee on Cancer (eighth edition). We examined whether there were statistical differences in SUVmax between each prognostic stage. The mean SUVmax values for clinical prognostic stages were as follow: stage 0, 2.2 ± 1.4; stage IA, 2.6 ± 2.1; stage IB, 4.2 ± 3.5; stage IIA, 5.2 ± 2.8; stage IIB, 7.7 ± 6.7; and stage III + IV, 7.0 ± 4.5. The SUVmax values for pathological prognostic stages were as follows: stage 0, 2.2 ± 1.4; stage IA, 2.8 ± 2.2; stage IB, 5.4 ± 3.6; stage IIA, 6.3 ± 3.1; stage IIB, 9.2 ± 7.5; and stage III + IV, 6.2 ± 5.2. There were significant differences in mean SUVmax between clinical prognostic stage 0 and ≥II (p < 0.001) and I and ≥II (p < 0.001). There were also significant differences in mean SUVmax between pathological prognostic stage 0 and ≥II (p < 0.001) and I and ≥II (p < 0.001). In conclusion, mean SUVmax increased with all stages up to prognostic stage IIB, and there were significant differences between several stages. The SUVmax of 18F-FDG PET/CT may contribute to prognostic stage stratification, particularly in early cases of breast cancers.

Keywords: breast cancer; positron emission tomography; standard uptake value; prognostic stage; American Joint Committee on Cancer

1. Introduction

Breast cancer staging is used to ascertain the extent of the disease, help implement a treatment plan, and predict prognosis [1]. Since 1977, the American Joint Committee on Cancer (AJCC) has published a staging system for breast cancer based on anatomic findings, including tumor size (T), nodal status (N), and metastases (M) [2]. The eighth
edition of the AJCC staging system introduced a new prognostic staging system that incorporates biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status, and tumor grade [2]. Since the publication of this new prognostic staging system, several studies have reported its correlation with prognosis in clinical settings [1,3,4]. The prognostic stage should be used as a primary staging system in countries where these biomarker tests are routinely performed for patient care, and cancer registries in the United States must use the prognostic stage group tables for reporting cases [2].

18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has the advantage of being able to evaluate both the morphology and glucose metabolism of the lesions [5]. It is useful in breast cancers to identify distant metastases or secondary cancers and is also used to predict prognosis and therapeutic effects [6–10]. Previous studies have shown that the maximum standardized uptake value (SUVmax), a common semiquantitative value of 18F-FDG PET/CT, correlates with ER, PR, HER2, and tumor grade [11–13]. However, the relationship between the AJCC prognostic stage, which is a complex concept including T, N, M, and biomarkers, and 18F-FDG PET/CT remains unclear.

This retrospective study examined whether the SUVmax of 18F-FDG PET/CT contributes to the stratification of the prognostic stage. This is the first study to investigate the relationship between prognostic stage and 18F-FDG PET/CT findings.

2. Materials and Methods

2.1. Study Design and Patients

This retrospective study enrolled consecutive patients who underwent 18F-FDG PET/CT for initial staging for breast cancer between January 2016 and December 2019. Among 699 18F-FDG PET/CT analyses performed for breast cancer patients during the study period, 361 18F-FDG PET/CT were excluded because they were performed to evaluate recurrent cancers and assess therapeutic efficacy. Altogether, 338 18F-FDG PET/CT analyses performed for initial staging were included. Four cancers of four patients were excluded, as the biomarkers required to determine both clinical and pathological prognostic stages were not pathologically diagnosed. Among the remaining 334 patients, 20 had two tumors and 2 had three tumors. A final total of 334 patients with 358 breast cancers were enrolled. Three patients had a history of contralateral breast cancer surgery. The remaining 331 patients had no history of breast-related disease.

Among the 314 patients who underwent surgery as an initial treatment, the mean interval between 18F-FDG PET/CT and surgery was 28.1 ± 23.6 days (range, 2–210 days), and among the 329 breast cancers biopsied prior to 18F-FDG PET/CT, the mean interval was 22.1 ± 11.3 days (range, 0–112 days).

2.2. 18F-FDG PET/CT Protocol

18F-FDG (3.7 MBq/kg; 0.1 mCi/kg) was administered intravenously in all patients after at least a 4 h fasting period. Whole-body images were then routinely obtained using a PET/CT system (Aquiduo or Celesteion, Canon Medical Systems, Tochigi, Japan). CT was also performed using the following parameters: pitch, 0.938; gantry rotation time, 0.5 s; table time, 30 mm/s; auto-exposure control (SD 20), 120 KVp; and slice thickness, 2.0 mm. Contrast materials were not used for CT examinations. Whole-body emission PET was performed after approximately 60 min of 18F-FDG administration using the following parameters: emission time per bed, 2 min; bed position, 9–10; slice thickness, 4.08 mm; and matrix, 144 × 144.

2.3. 18F-FDG PET/CT Analysis

SUVmax data for the breast cancers were obtained from diagnostic reports provided by nuclear medicine experts, with more than eight years of experience, who performed the initial staging of breast cancer. A circular region of interest (ROI) was set on the
highest uptake of the primary breast cancer to calculate SUVmax using Vox-base version 2.8 (J-MAC SYSTEM, Inc., Hokkaido, Japan). The ROI was set avoiding nipples, which are areas with high physiological accumulation. When the accumulation of lesions was low and distinguishing the lesion from the background mammary gland was difficult, the position of ROI was determined by referring to contrast-enhanced breast magnetic resonance imaging. All images were measurable and had few motion artifacts.

2.4. Clinicopathological Evaluation

Age, gender, and pathological information of the patients were obtained from medical records. Surgical specimens of breast tissue were cut by pathologists into 5–10-mm contiguous sections, and thinner slices were added as required. All surgical and biopsy cases were diagnosed by a pathologist who recorded the following histological features: tumor size of invasive component; nuclear grade (1, 2, or 3); and receptor status (ER, PR, and HER2). AJCC recommends using histological grade as the tumor grade; however, nuclear grade was used in this study. A cutoff of 1% was used for ER and PR assays according to the American Society of Clinical Oncology/College of American Pathologists guidelines [14]. HER2 status was defined as positive if 3+ on immunohistochemistry or fluorescence in situ hybridization demonstrated gene amplification [15].

2.5. Anatomical and Prognostic Stages

The anatomical stage was based solely on the anatomical extent of the cancer, as defined by the T, N, and M categories [2]. Staging of the 314 cancers was performed using available surgical specimens, and the remaining 44 were staged using whole-body 18F-FDG PET/CT, contrast-enhanced breast magnetic resonance imaging, and breast ultrasonography, as either only biopsy specimens were available or neoadjuvant therapy was given. A pathological prognostic stage was used for patients who had undergone surgical resection as the initial treatment for their cancer before receiving systemic or radiation therapy and was based on tumor grade and ER, PR, and HER2 status from surgery and resected tissue as well as T, N, and M stage [2]. A clinical prognostic stage was applied to cancers with available biopsy specimens. Among the 358 cancers, a pathological prognostic stage was determined in 313 and a clinical prognostic stage was determined in 323. The relationship between the stages is shown in Tables 1 and 2 [2,16].

2.6. Statistical Analysis

We examined whether the prognostic stage could be stratified by SUVmax alone, irrespective of TNM stage and biomarker status. The clinical and pathological prognostic stages were grouped as follows: stage 0, I, II, and III + IV. First, the Kolmogorov–Smirnov test was used to examine if the variables were normally distributed. The Kruskal–Wallis test, which is a nonparametric test, was performed to examine whether the null hypothesis was rejected by some groups, assuming normality. In the subsequent Dunn–Bonferroni test, we examined whether there was a significant difference in mean SUVmax between the stages. All statistical analyses were performed using IBM SPSS Statistics version 24 (International Business Machines Corporation, Armonk, NY, USA). p-Values < 0.05 were considered to indicate statistical significance. Data are presented as mean SUVmax ± standard deviation.
Table 1. Correspondence table showing anatomical and clinical prognostic stages.

| TNM | Grade | Clinical Prognostic Stage | Anatomical Stage |
|-----|-------|---------------------------|------------------|
| TisN0 | G1–3 | Triple Positive HR+, HER2+ | IA |
| T1N0 | G1/G2 | Luminal-Like HR+, HER2- | IA |
| G3 | HER2-Like HR+, HER2+ | IA |
| T2N0 | G3 | HR-, HER2- | IA |
| T3N0 | G3 | Triple Negative HR-, HER2- | IA |
| T0–1N1mi | G1/G2 | HR+, HER2+ | IA |
| T1N1 | G1/G2 | HER2-Like HR+, HER2+ | IA |
| T2N1 | G3/G2 | HR-, HER2- | IA |
| T1N2 | G2 | Triple Negative HR-, HER2- | IA |
| T3N1 | G3 | HR+, HER2+ | IA |
| T4N0–2 | G1/G2 | HER2-Like HR+, HER2+ | IA |
| G3 | HR-, HER2- | IA |
| Any N3 | G3 | Triple Negative HR-, HER2- | IA |

G, nuclear grade; HER2+, HER2 receptor-positive; HER2-, HER2 receptor-negative; HR+, estrogen receptor-positive/progesterone receptor-positive; HR-, estrogen receptor-negative/progesterone receptor-negative; HR±, estrogen receptor-positive/progesterone receptor-positive and estrogen receptor-negative/progesterone receptor-negative; Tis, carcinoma in situ. Gray, stage 0; Pale yellow, stage IA; Yellow, stage IB; Pale green, stage IIA; Green, stage IIB; Pale pink, stage IIIA; Pink, stage IIIB; Vivid pink, stage IIIC; Blue, stage IV.

Table 2. Correspondence table showing anatomical and pathological prognostic stages.

| TNM | Grade | Clinical Prognostic Stage | Anatomical Stage |
|-----|-------|---------------------------|------------------|
| TisN0 | G1–3 | Triple Positive HR+, HER2+ | IA |
| T1N0 | G1/G2 | Luminal-Like HR+, HER2- | IA |
| G3 | HER2-Like HR+, HER2+ | IA |
| T2N0 | G3 | HR-, HER2- | IA |
| T3N0 | G3 | Triple Negative HR-, HER2- | IA |
| T0–1N1mi | G1/G2 | HR+, HER2+ | IA |
| T1N1 | G1/G2 | HER2-Like HR+, HER2+ | IA |
| T2N1 | G3/G2 | HR-, HER2- | IA |
| T1N2 | G2 | Triple Negative HR-, HER2- | IA |
| T3N1 | G3 | HR+, HER2+ | IA |
| T4N0–2 | G1/G2 | HER2-Like HR+, HER2+ | IA |
| G3 | HR-, HER2- | IA |
| Any N3 | G3 | Triple Negative HR-, HER2- | IA |
| Any M1 | G1–3 | HR+, HER2+ | IA |

G, nuclear grade; HER2+, HER2 receptor-positive; HER2-, HER2 receptor-negative; HR+, estrogen receptor-positive/progesterone receptor-positive; HR-, estrogen receptor-negative/progesterone receptor-negative; HR±, estrogen receptor-positive/progesterone receptor-positive and estrogen receptor-negative/progesterone receptor-negative; Tis, carcinoma in situ. Gray, stage 0; Pale yellow, stage IA; Yellow, stage IB; Pale green, stage IIA; Green, stage IIB; Pale pink, stage IIIA; Pink, stage IIIB; Vivid pink, stage IIIC; Blue, stage IV.

3. Results

3.1. Patients

A total of 358 breast cancers in 334 patients were enrolled. Among the 334 patients, 20 had two cancers and 2 had three tumors. All patients were female, and the mean age was 58.9 ± 12.9 years (range, 26–87 years). Surgery revealed invasive ductal carcinomas of no special type (n = 225), ductal carcinoma in situ (n = 31), invasive lobular carcinoma (n = 22), mucinous carcinoma (n = 13), invasive micropapillary carcinoma (n = 7), apocrine carcinoma (n = 6), mixed invasive ductal and lobular carcinoma (n = 3), lobular carcinoma in situ (n = 2), Paget’s disease (n = 2), squamous cell carcinoma (n = 1), microinvasive carcinoma (n = 1), and papillary carcinoma (n = 1). The remaining 44 lesions were diagnosed with invasive ductal carcinomas of no special type (n = 35), invasive lobular carcinoma (n = 4), mucinous carcinoma (n = 1), and apocrine carcinoma (n = 1), ductal carcinoma (n = 1); presence or absence of invasion was unknown), invasive carcinoma (n = 1; unknown tissue subtype), and invasive ductal carcinoma with metaplastic carcinoma component by biopsy (n = 1). The clinical prognostic stage was determined in 323 cancers, and the pathological prognostic stage was determined in 313 cancers. The biomarker status of the cancers is shown in Table 3. HER2 status or nuclear grade was unknown in some cases, but cases in which the missing status did not change the prognostic stage were included.
Table 3. Clinicopathological findings.

|                     | Anatomical Stage (n = 358) | Clinical Prognostic Stage (n = 323) | Pathological Prognostic Stage (n = 313) |
|---------------------|-----------------------------|------------------------------------|----------------------------------------|
| Age (years)         | 58.9 ± 12.9                 | 58.9 ± 12.9                        | 59.0 ± 12.9                           |
| T                   | Tis 37 (10.3%)              | 36 (11.1%)                         | 36 (11.5%)                            |
|                    | 1 196 (54.7%)               | 175 (54.2%)                        | 186 (59.4%)                           |
|                    | 2 100 (27.9%)               | 88 (27.2%)                         | 82 (26.2%)                            |
|                    | 3 13 (3.6%)                 | 12 (3.7%)                          | 9 (2.9%)                              |
|                    | 4 12 (3.4%)                 | 12 (3.7%)                          | 0 (0%)                                |
| N                   | 248 (69.3%)                 | 225 (69.7%)                        | 232 (74.1%)                           |
|                    | 72 (20.1%)                  | 64 (19.8%)                         | 57 (18.2%)                            |
|                    | 17 (4.7%)                   | 15 (4.6%)                          | 16 (5.1%)                             |
|                    | 21 (5.9%)                   | 19 (5.9%)                          | 8 (2.6%)                              |
| M                   | 348 (97.2%)                 | 313 (96.9%)                        | 312 (99.7%)                           |
|                    | 10 (2.8%)                   | 10 (3.1%)                          | 1 (0.3%)                              |
| ER                  | 283 (79.1%)                 | 255 (78.9%)                        | 256 (81.8%)                           |
|                    | 75 (20.9%)                  | 68 (21.1%)                         | 57 (18.2%)                            |
| PR                  | 261 (72.9%)                 | 236 (73.1%)                        | 237 (75.7%)                           |
|                    | 97 (27.1%)                  | 87 (26.9%)                         | 76 (24.3%)                            |
| HER2                | 52 (14.5%)                  | 47 (14.6%)                         | 41 (13.1%)                            |
|                    | 283 (79.1%)                 | 256 (79.3%)                        | 252 (80.5%)                           |
| Unknown             | 23 (6.4%)                   | 20 (6.2%)                          | 20 (6.4%)                             |
| Nuclear grade       | 188 (51.7%)                 | 168 (52.0%)                        | 161 (51.4%)                           |
|                    | 68 (19.0%)                  | 66 (20.4%)                         | 58 (18.5%)                            |
|                    | 97 (27.1%)                  | 82 (25.4%)                         | 84 (26.8%)                            |
| Unknown             | 8 (2.2%)                    | 7 (2.2%)                           | 10 (3.2%)                             |

The table shows the clinicopathological findings for each group. Age is presented as mean ± SD; other measurements are presented as number (%). ER, estrogen receptor; HER2, human epidermal growth factor receptor; M, metastasis status; N, nodal status; PR, progesterone receptor; T, tumor status; Tis, carcinoma in situ.

3.2. Anatomical and Prognostic Stages

Tables 4 and 5 show the number of cancers assigned to each stage. According to the AJCC criteria, 33 cancers (10.2%) were upstaged, 206 cancers (63.8%) remained unchanged, and 84 cancers (26.0%) were downstaged from anatomical stage to clinical prognostic stage. In addition, 17 cancers (5.4%) were upstaged, 201 cancers (64.2%) remained unchanged, and 95 cancers (30.4%) were downstaged from anatomical stage to pathological prognostic stage [2].

Table 4. Migration from anatomical to clinical prognostic stage.

| Anatomical stage | Clinical Prognostic Stage |
|------------------|---------------------------|
| 0                | 1A 1B II A II B III A III B III C IV Total |
| 0                | 36 *                        | 36 |
| 1A               | 135 *                       | 145 |
| 1B               | 4                           | 4 |
| II A             | 2 44 7 * 8 1 4 16 6 * 5 2 16 4 29 |
| II B             | 6 3 * 5 3 9 4 * 10 * 10 323 |
| Total            | 36 142 56 29 14 3 24 9 10 |
Table 5. Migration from anatomical to pathological prognostic stage.

| Pathological Prognostic Stage | 0   | IA  | IB  | IIA | IIB | IIIA | IIIB | IIIC | IV  | Total |
|-------------------------------|-----|-----|-----|-----|-----|------|------|------|-----|-------|
| Anatomical stage              |     |     |     |     |     |      |      |      |     |       |
| 0                             | 36  | 144 | 48  | 7   | 8   | 5    | 4    | 4    | 1   | 3173  |
| IA                            | 36  | 8   | 11  | 1    | 1    | 4    | 1    |      |     | 152   |
| IB                            |     | 4   |     |     |     |      |      |      |     |       |
| IIA                           | 48  | 7   | 6   | 3    | 4    |      |      |      |     | 67    |
| IIB                           |     | 8   | 3   | 6    | 4    | 1    | 4    |      |     | 28    |
| IIIA                          | 7   | 5   | 5   | 3    | 4    |      |      |      |     | 17    |
| IIIB                          | 5   |     |     |     |      |      |      |      |     |       |
| IIIIC                         |     |     |     |     |      |      |      |      |     |       |
| IV                            | 4   | 4   | 4   | 1    |      |      |      |      |     | 8     |
| Total                         | 36  | 203 | 28  | 14   | 12   | 11   | 4    | 4    | 1   | 313   |

* Number of cancers that did not migrate.

3.3. SUVmax at Each Prognostic Stage

The mean SUVmax values for the clinical prognostic stage were found to be 2.2 ± 1.4 (stage 0), 2.6 ± 2.1 (stage IA), 4.2 ± 3.5 (stage IB), 5.2 ± 2.8 (stage IIA), 7.7 ± 6.7 (stage IIB), 7.9 ± 6.0 (stage IIIA), 5.8 ± 4.2 (stage IIIB), 9.4 ± 6.0 (stage IIIC), 7.3 ± 2.6 (stage IV), and 7.0 ± 4.5 (stage III + IV) (Table 6). The mean SUVmax values for the pathological prognostic stage were found to be 2.2 ± 1.4 (stage 0), 2.8 ± 2.2 (stage IA), 5.4 ± 3.6 (stage IB), 6.3 ± 3.1 (stage IIA), 9.2 ± 7.5 (stage IIB), 5.4 ± 3.9 (stage IIIA), 3.0 ± 0.5 (stage IIIB), 11.7 ± 7.8 (stage IIIC), 5.3 (stage IV), and 6.2 ± 5.2 (stage III + IV) (Table 4). Boxplots of the SUVmax for each prognostic stage are shown in Figures 1 and 2.

Table 6. SUVmax of each stage.

| Clinical Prognostic Stage | Pathological Prognostic Stage |
|---------------------------|-------------------------------|
|                           | (n = 323)                     | (n = 313)                     |
| 0                         | 2.2 ± 1.4 (36)                | 2.2 ± 1.4 (36)                |
| IA                        | 2.6 ± 2.1 (142)               | 2.8 ± 2.2 (203)               |
| IB                        | 4.2 ± 3.5 (36)                | 5.4 ± 3.6 (28)                |
| IIA                       | 5.2 ± 2.8 (29)                | 6.3 ± 3.1 (14)                |
| IIB                       | 7.7 ± 6.7 (14)                | 9.2 ± 7.5 (12)                |
| IIIA                      | 7.9 ± 6.0 (3)                 | 5.4 ± 3.9 (11)                |
| IIIB                      | 5.8 ± 4.2 (24)                | 3.0 ± 0.5 (4)                 |
| IIIC                      | 9.4 ± 6.0 (9)                 | 11.7 ± 7.8 (4)                |
| IV                        | 7.3 ± 2.6 (10)                | 5.3 (1)                       |
| III + IV *                | 7.0 ± 4.5 (46) *              | 6.2 ± 5.2 (20) *              |

Mean SUVmax ± standard deviation (number of cancers). * Stages III and IV were present in low numbers and were combined.

The Kolmogorov–Smirnov test did not show normal distribution in stage 0–II of the clinical prognostic stage (p < 0.001–0.009) and 0–II + IV (p < 0.001–0.022) of the pathological prognostic stage. The Kruskal–Wallis test showed that there was a significant difference in both the clinical and pathological prognostic stages (p < 0.001). There were significant differences in the mean SUVmax between the clinical prognostic stage 0 and ≥II (p < 0.001) and I and ≥II (p < 0.001). There were also significant differences in the mean SUVmax between the pathological prognostic stage 0 and ≥II (p < 0.001) and I and ≥II (p < 0.001) (Table 7).
IIIC 9.4 ± 6.0 (9) 11.7 ± 7.8 (4)  
IV 7.3 ± 2.6 (10) 5.3 (1)  
III + IV * 7.0 ± 4.5 (46) * 6.2 ± 5.2 (20) *  
Mean SUVmax ± standard deviation (number of cancers). * Stages III and IV were present in low numbers and were combined.

Figure 1. Boxplot of clinical prognostic stage. Boxplots showing the distribution of SUV max for each clinical prognostic stage. Stage III and IV are summarized at the right end of the graph owing to the small sample size at each stage. The sample size for each stage was 36 for stage 0, 198 for stage I, 43 for stage II, and 46 for stage III + IV.

Figure 2. Boxplot of pathological prognostic stage. Boxplots showing the distribution of SUV max for each pathological prognostic stage. Stage III and IV are summarized at the right end of the graph owing to the small sample size at each stage. The sample size for each stage was 36 for stage 0, 231 for stage I, 26 for stage II, and 20 for stage III + IV.
Table 7. Statistical analysis of staging.

| Pathological prognostic stage | Clinical Prognostic Stage |
|-------------------------------|---------------------------|
|                               | 0            | I      | II     | III + IV |
| 0                             | 1.000        | <0.001 | <0.001 |
| I                             | 0.459        | <0.001 | <0.001 |
| II                            | <0.001 *     | <0.001 | 1.000  |
| III + IV                      | <0.001 *     | 0.004  | 1.000  |

*p*-Values of Dunn-Bonferroni test between two corresponding groups are shown in the cross table. The upper rows show the results of the clinical prognostic stage (blue letters), and the lower rows show the results of the pathological prognostic stage. For instance, *p* = 1.000 for stage 0 vs. 1 in the clinical prognostic stage and *p* = 0.459 for stage 0 vs. 1 in the pathological prognostic stage. * Statistically significant.

Some cases with low tumor SUVmax were downstaged from the anatomical to the prognostic stage (Figure 3), and some cases with high tumor SUVmax were upstaged from the anatomical stage to the prognostic stage (Figure 4).

Figure 3. A woman in her 60s was found to have a left invasive ductal carcinoma of no special type by surgery (arrows). (a) Breast ultrasonography (B mode), (b) contrast-enhanced breast magnetic resonance image (axial image of early phase of contrast-enhanced), and (c) whole-body positron emission tomography. Pathological analysis revealed T2N0M0, nuclear grade 1, positive estrogen receptor, positive progesterone receptor, and negative human epidermal growth factor receptor 2 (not shown). She was found to have an SUVmax of 1.4, anatomical stage IIA, clinical prognostic stage IB, and pathological prognostic stage IA.
Figure 4. A woman in her 60s was found to have a right invasive ductal carcinoma of no special type by surgery (arrows). (a) Breast ultrasonography (B mode), (b) contrast-enhanced breast magnetic resonance image (axial image of early phase of contrast-enhanced), and (c) whole-body positron emission tomography. Pathological analysis revealed T1cN0M0, nuclear grade 3, negative estrogen receptor, negative progesterone receptor, and negative human epidermal growth factor receptor 2 (not shown). She was found to have an SUVmax of 12.5, anatomical stage IA, clinical prognostic stage IB, and pathological prognostic stage IB.

4. Discussion

The present study revealed that the mean SUVmax increased with all stages up to prognostic stage IIB, and there were significant differences in mean SUVmax between clinical prognostic stages 0 and ≥II, and I and ≥II. There were also significant differences in mean SUVmax between pathological prognostic stage 0 and ≥II, and I and ≥II. The SUVmax of 18F-FDG PET/CT may contribute to the stratification of the prognostic stage, particularly in early breast cancers. To our knowledge, this is the first study to investigate the relationship between prognostic stage and 18F-FDG PET/CT findings.

It has long been reported that biomarkers, including ER, PR, HER2, and tumor grade, correlate with prognosis [17–20]; the AJCC recently published a prognostic staging system that incorporates this concept [2]. The incorporation of biomarkers into the prognostic staging system results in stage migration for certain patients [21]. For example, triple-negative tumors are generally “upstaged” in the prognostic stage, whereas HER2 expression is a “downstaging” factor [2,21]. Abdel-Rahman reported that all pairwise hazard ratio comparisons between different stages were significant among 209,304 patients according to prognostic stages [4]. Weiss et al. reported that the prognostic stage provided more accurate stratification with respect to disease-specific survival than the anatomical stage among 3327 patients with stage I–IIIC and 54,727 patients with stage I–IV breast cancer [1]. Wang et al. reported that the prognostic stage was an independent prognostic factor among 10,053 locally advanced breast cancers according to multivariate analysis [3]. These findings highlight the importance of the prognostic stage rather than the anatomical stage for prognosis prediction and treatment strategy. However, the prognostic stage is based on pathological findings, and preoperative diagnostic imaging alone is not sufficient.

18F-FDG PET/CT is a non-invasive approach that shows morphological findings as well as metabolic activities associated with malignancy [5,6]. Several studies have reported the usefulness of 18F-FDG PET/CT for predicting prognosis in breast cancer. Kadoya et al. reported that univariate and multivariate analyses identified high SUVmax as an independent prognostic factor among 344 patients with clinical stage I–III breast cancer, using a SUVmax cutoff value of 3.0 [6]. A meta-analysis showed that breast cancer patients with high SUVmax were at high risk of adverse events or death, with high metabolic tumor...
volume predicting a high risk of death and high total lesion glycolysis predicting a high risk of adverse events [9]. Previous studies suggest that high FDG uptake is correlated with bigger tumor size, negative ER expression, negative PR expression, positive HER2 expression, and high histological grade [11–13]. HER2 status is conflicting, as while HER2 positivity is a good prognostic factor, it is associated with a high SUVmax. There is still no consensus on how each biomarker affects SUVmax when combined.

In the present study, there was no change from anatomical stage to clinical prognostic stage in 63.8% of cases and no change from anatomical stage to pathological prognostic stage in 64.2% of cases (Tables 3 and 4). Anatomical and prognostic stages can be considered to be very different staging systems. The prognostic stage is an ideal staging system for the prediction of prognosis, whereas pathological diagnosis is required, and the correspondence table is complicated. There is often a difference between the biopsy and surgical pathology results. In the present study, two cases were upstaged in the clinical prognostic stage but downstaged in the pathological prognostic stage, and one case showed the opposite findings. We focused on 18F-FDG PET/CT as a tool to stratify prognostic staging. The SUVmax increased as the stage increased up to prognostic stage IIB, and there was a significant difference between some stages (Tables 6 and 7, Figures 1 and 2). HER2 status, which shows conflicting results for high SUVmax and good prognostic potential, did not appear to be a problem in the present study. It is possible that ER, PR, and nuclear grade mitigated the effects of HER2 status. Furthermore, since the present study included consecutive cases during the study period, there were few HER2-positive cancers. Verifying whether prognosis worsens with an increase in the SUVmax of HER2-positive breast cancers is essential. The mean SUVmax was found to be higher in stage I than in stage 0; however, no significant difference was observed between stage 0 and I in the clinical and pathological prognostic stages (Tables 6 and 7). This does not appear to be important from a prognostic point of view because the five-year survival rate for the prognostic stage I is very good (above 97.5%) [1]. In addition, it was difficult to demonstrate a significant difference in the higher stages of II vs. III + IV (Table 7). This may be because lymph node status is more important than the glucose metabolic activity of primary breast cancer in the higher stages; therefore, evaluation of SUVmax in the primary lesion may be insufficient, and total primary and metastatic lesion glycolysis, which is calculated by multiplying the metabolic tumor volume of a lesion with its corresponding mean SUV, may be a better indicator of prognosis [22]. Another reason for these findings may be that only a small number of cases of higher stages were included in this study. Additional studies with increased numbers are required.

One limitation of the present study is that it was retrospective in nature. Second, it had a relatively small sample size. The number of types of breast cancers included in this study may have affected the results, but statistical analysis based on types was not possible owing to the small sample size. Third, while the AJCC recommends histological grade as the tumor grade, this study used nuclear grade. Fourth, we did not examine whether uptake of 18F-FDG correlates with actual prognosis. However, this correlation has been extensively discussed previously and we examined its association with the prognostic stage in the present study. Finally, there is an opinion that 18F-FDG PET/CT is not required for early-stage breast cancer. However, it has been reported that up to 44% of patients diagnosed with ductal carcinoma in situ by biopsy develop invasive cancer [23], and it may not be possible to assert early-stage breast cancer by biopsy alone. Furthermore, as this study suggested that the prognostic stage is associated with SUVmax, it may be recommended that 18F-FDG PET/CT be performed to estimate the malignancy of breast cancer.

5. Conclusions

SUVmax of 18F-FDG PET/CT may allow stratification of the prognostic stage, particularly in early breast cancers. This non-invasive and simple method may be clinically useful and allow tumor properties to be evaluated to predict the prognosis of breast cancer patients.
Author Contributions: Conceptualization, T.F. and K.K.; methodology, T.F. and J.T.; software, I.O.; validation, L.K., Y.Y., K.N. and E.Y.; formal analysis, M.M.; investigation, T.H., G.O. and T.N.; resources, T.H., G.O. and T.N.; data curation, M.M.; writing—original draft preparation, M.M.; writing—review and editing, T.F. and K.K.; visualization, M.M.; supervision, U.T.; project administration, U.T.; funding acquisition, M.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of Tokyo Medical and Dental University (protocol code, M2019-137; 19 September 2019).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Weiss, A.; Mac Gregor, M.C.; Lichtensztajn, D.; Yi, M.; Tadros, A.; Hortobagyi, G.N.; Giordano, S.H.; Hunt, K.K.; Mittendorf, E.A. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared with the Anatomic Stage in Breast Cancer. JAMA Oncol. 2018, 4, 203–209. [CrossRef] [PubMed]

2. Giuliani, A.E.; Edge, S.B.; Hortobagyi, G.N. Eighth ditionedition of the AJCC cancer staging manual: Breast cancer. Ann. Surg. Oncol. 2018, 25, 1783–1785. [CrossRef]

3. Wang, M.; Chen, H.; Wu, K.; Ding, A.; Zhang, M.; Zhang, P. Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database. Breast 2018, 37, 56–63. [CrossRef] [PubMed]

4. Abdel-Rahman, O. Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Res. Treat. 2018, 168, 269–275. [CrossRef] [PubMed]

5. Mori, M.; Fujioka, T.; Katsuta, L.; Tsuichia, J.; Kubota, K.; Kasahara, M.; Oda, G.; Naka, T.; Onishi, I.; Tateishi, U. Diagnostic performance of time-of-flight PET/CT for evaluating nodal metastasis of the axilla in breast cancer. Nucl. Med. Commun. 2019, 40, 958–964. [CrossRef] [PubMed]

6. Kadoya, T.; Aogi, K.; Kiyoto, S.; Sugawara, Y.; Okada, M. Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: A multi-institute study. Breast Cancer Res. Treat. 2013, 141, 269–275. [CrossRef]

7. Ishiba, T.; Naka, T.; Sato, T.; Nagahara, M.; Oda, G.; Sugimoto, H.; Kasahara, M.; Hosoya, T.; Kubota, K.; Fujioka, T.; et al. Efficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in breast cancer patients received neoadjuvant chemotherapy. SpringerPlus 2015, 4, 817. [CrossRef]

8. Ahn, S.G.; Lee, M.; Jeon, T.J.; Han, K.; Lee, H.M.; Lee, S.A.; Ryu, Y.H.; Son, E.J.; Jeong, J. [18F]-Fluorodeoxyglucose Positron Emission Tomography Can Contribute to Discriminate Patients with Poor Prognosis in Hormone Receptor-Positive Breast Cancer. PLoS ONE 2014, 9, e105905. [CrossRef]

9. Wen, W.; Xuan, D.; Hu, Y.; Li, X.; Liu, L.; Xu, D. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography/computed tomography in patients with breast cancer: A systematic review and meta-analysis. PLoS ONE 2019, 14, e0225959. [CrossRef]

10. Fujioka, T.; Kubota, K.; Kikuchi, Y.; Tsuichia, J.; Tateishi, U.; Kasahara, M.; Oda, G.; Ishiba, T.; Naka, T. The feasibility of using 18F-FDG-PET/CT in patients with mucinous breast carcinoma. Nucl. Med. Commun. 2018, 39, 1033–1038. [CrossRef]

11. Shimoda, W.; Hayashi, M.; Murakami, K.; Oyama, T.; Sunagawa, T. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer 2007, 14, 260–268. [CrossRef]

12. Sanli, Y.; Kuyumcu, S.; Ozkan, Z.G.; Işık, G.; Karanlık, H.; Güzelbey, B.; Turkmen, B.; Ozel, S.; Yavuz, E.; Muc, A. Increased FDG uptake in breast cancer is asso-ciated with prognostic factors. Ann. Nucl. Med. 2012, 26, 345–350. [CrossRef]

13. Osborne, J.R.; Port, E.; Onen, M.; Doane, A.S.; Yeung, H.; Gerald, W.; Cook, J.B.; Larson, S. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: Microarray and immunohistochemical analysis. J. Nucl. Med. 2010, 51, 543–550. [CrossRef] [PubMed]

14. Hammond, M.E.; Hayes, D.F.; Dowsett, M.; Allred, D.C.; Hagerty, K.L.; Badve, S.; Francis, G.; Goldstein, N.S.; Hayes, M.; Hicks, D.G.; et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and proges-terone receptors in breast cancer. J. Clin. Oncol. 2010, 28, 2784–2795. [CrossRef] [PubMed]

15. Wolff, A.; Hammond, M.E.H.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.; Bilous, M.; Fitzgibbons, P.; et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J. Clin. Oncol. 2013, 31, 3997–4013. [CrossRef]
16. Koh, J.; Kim, M.J. Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage. *Korean J. Radiol.* **2019**, *20*, 69–82. [CrossRef] [PubMed]

17. Harris, L.N.; Ismaila, N.; McShane, L.M.; Andre, F.; Collyar, D.E.; Gonzalez-Angulo, A.M.; Hammond, E.H.; Kuderer, N.M.; Liu, M.C.; Mennel, R.G.; et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J. Clin. Oncol.* **2016**, *34*, 1134–1150. [CrossRef] [PubMed]
18. Yi, M.; Mittendorf, E.A.; Cormier, J.N.; Buchholz, T.; Bilimoria, K.; Sahin, A.A.; Hortobagyi, G.N.; Gonzalez-Angulo, A.M.; Luo, S.; Buzdar, A.U.; et al. Novel Staging System for Predicting Disease-Specific Survival in Patients with Breast Cancer Treated with Surgery As the First Intervention: Time to Modify the Current American Joint Committee on Cancer Staging System. *J. Clin. Oncol.* 2011, 29, 4654–4661. [CrossRef] [PubMed]

19. Veronesi, U.; Zurrida, S.; Viale, G.; Galimberti, V.; Arnone, P.; Nolè, F. Rethinking TNM: A Breast Cancer Classification to Guide to Treatment and Facilitate Research. *Breast J.* 2009, 15, 291–295. [CrossRef] [PubMed]

20. Bagaria, S.P.; Ray, P.S.; Sim, M.-S.; Ye, X.; Shamonki, J.M.; Cui, X.; Giuliano, A.E. Personalizing Breast Cancer Staging by the Inclusion of ER, PR, and HER2. *JAMA Surg.* 2014, 149, 125–129. [CrossRef] [PubMed]

21. Kalli, S.; Semine, A.; Cohen, S.; Naber, S.P.; Makim, S.S.; Bahl, M. American Joint Committee on Cancer’s Staging System for Breast Cancer, Eighth Edition: What the Radiologist Needs to Know. *Radiographics* 2018, 38, 1921–1933. [CrossRef]

22. Qu, Y.-H.; Long, N.; Ran, C.; Sun, J. The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer. *Clin. Transl. Oncol.* 2021, 23, 620–627. [CrossRef]

23. Shin, Y.J.; Kim, S.M.; La Yun, B.; Jang, M.; Kim, B.; Lee, S.H. Predictors of Invasive Breast Cancer in Patients with Ductal Carcinoma in Situ in Ultrasound-Guided Core Needle Biopsy. *J. Ultrasound Med.* 2019, 38, 481–488. [CrossRef]